It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Defective CFTR leads to accumulation of dehydrated viscous mucus within the small intestine, luminal acidification and altered intestinal motility, resulting in blockage. These changes promote gut microbial dysbiosis, adversely influencing the normal proliferation and differentiation of intestinal epithelial cells. Using Illumina 16S rRNA gene sequencing and immunohistochemistry, we assessed changes in mucosa-attached microbiome and epithelial cell profile in the small intestine of CF mice and a CF patient compared to wild-type mice and non-CF humans. We found increased abundance of pro-inflammatory Escherichia and depletion of beneficial secondary bile-acid producing bacteria in the ileal mucosa-attached microbiome of CFTR-null mice. The ileal mucosa in a CF patient was dominated by a non-aeruginosa Pseudomonas species and lacked numerous beneficial anti-inflammatory and short-chain fatty acid-producing bacteria. In the ileum of both CF mice and a CF patient, the number of absorptive enterocytes, Paneth and glucagon-like peptide 1 and 2 secreting L-type enteroendocrine cells were decreased, whereas stem and goblet cell numbers were increased. These changes in mucosa-attached microbiome and epithelial cell profile suggest that microbiota-host interactions may contribute to intestinal CF disease development with implications for therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Liverpool, Department of Infection Biology and Microbiomes, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
2 University of Liverpool, Department of Infection Biology and Microbiomes, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); University of Al-Qadisiyah, Department of Physiology, Biochemistry and Pharmacology, College of Veterinary Medicine, Al Diwaniyah, Iraq (GRID:grid.440842.e) (ISNI:0000 0004 7474 9217)
3 Arrowe Park University Teaching Hospital NHS Trust, Wirral, UK (GRID:grid.10025.36); Aintree University Hospital, Gastrointestinal and Liver Services, Liverpool, Merseyside, UK (GRID:grid.411255.6) (ISNI:0000 0000 8948 3192)
4 Sheffield Children’s Hospital NHS Trust, Sheffield, UK (GRID:grid.413991.7) (ISNI:0000 0004 0641 6082)
5 Sheffield Children’s Hospital NHS Trust, Histopathology Department, Sheffield, UK (GRID:grid.413991.7) (ISNI:0000 0004 0641 6082)
6 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
7 Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
8 University of Bristol, School of Physiology, Pharmacology and Neuroscience, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)